Circadian Clock Profiling for Cancer Treatment Timing
Spin-Off
Project WebsiteThe circadian clock is our internal time-generating system that rules our sleep and wake cycles and molecular processes like metabolism and cell division. We all have our own personal circadian clock, meaning metabolism and cell division happen at different times of the day for each of us. Furthermore, over 50% of FDA-approved drugs target 24h-rhythmic genes, but currently these circadian rhythms are not taken into consideration in clinical care.
Angela Relógio
((former Charité), MSH Medical School Hamburg)
Project Lead
The TimeTeller team has developed a non-invasive method to profile the personal circadian rhythm using an easy, risk-free, at-home test; you send your samples to TimeTeller and they’ll analyze and predict the optimal time windows for a given drug. The TimeTeller platform can ultimately be applied across clinical indications, from cancer to neurodegenerative diseases, diabetes and more, from pharma to clinic. The team is currently participating in clinical studies on ovarian and colon cancer and started studies in the field of pedriatic leukemia and Parkinson’s Disease.
Team TimeTeller combines the expertise of systems and molecular biologists, computational scientists, a clinical trials assistant and a product developer. TimeTeller is currently running a feasibility study at the Charité. Furthermore, the team is actively fundraising, looking for partnering in pharma, and preparing to spin off by the end of this year.
In May 2024, the German Startup Awards awarded founder Angela Relógio with the Newcomer of the Year award.
